The liquid biopsy with the cobas® EGFR Mutation Test v2 performed in 419 patients from the AURA3 trial showed that the concordance with tissue biopsies was lower for the EGFR p. T790M mutation than for the other EGFR activating mutations (51% for p. T790M, 82% for Del19, and 68% for p. L858R) [28] This underscored the relevance of performing tissue rebiopsies in case of negative plasma results at tumor progression, where a p. T790M is suspected. This evidence concerns the gene EGFR and neoplasm.